WENA (Anew Medical, Inc.) שולי רווח גולמי

Anew Medical, Inc. (WENA) relies on a compact staff of scientists motivated by equity stakes. An efficient gross margin demonstrates the results of this strategy, where 0.00 is the current value of the indicator. The company is developing gene therapies to combat ALS and Alzheimer's disease, planning to monetize brain regeneration methods. Intellectual property protection provides a competitive advantage while FDA verdicts are pending.
פילוחים אנליטיים ודוחות נתונים של חברת Anew Medical (WENA)

Gross margin determines the portion of revenue remaining after covering direct production costs, which characterizes the business's operational cushion. The trend in the gross margin rate allows for an assessment of cost management efficiency and the pace of solvency recovery. For Anew Medical, Inc. (WENA), this calculation is critical, as it reflects the profitability of developing Klotho protein therapy to combat neurodegeneration and ALS.